NeuroPace, Inc. (NASDAQ:NPCE) Stock Has Average Target Price of $20.50

NeuroPace, Inc. (NASDAQ:NPCE – Get Free Report) has received an average recommendation of “Hold” from the eleven ratings firms that are covering the company, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell rating, five have given a hold rating and five have given a buy rating to the company. The average 12 month target price among brokers that have issued a report on the stock in the last year is $13.11.

Several research analysts have recently weighed in on the stock. JPMorgan Chase & Co. lowered shares of NeuroPace from an “overweight” rating to a “neutral” rating and lowered their price objective for the stock from $20.00 to $9.00 in a research note on Friday, November 13th. KeyCorp decreased their target price on NeuroPace from $18.00 to $14.00 and set an “overweight” rating on the stock in a report on Friday, November 13th. Cantor Fitzgerald cut their price target on NeuroPace from $21.00 to $12.00 and set an “overweight” rating for the company in a report on Friday, November 13th. HC Wainwright dropped their price objective on shares of NeuroPace from $20.00 to $12.00 and set a “buy” rating on the stock in a research report on Monday. Finally, Weiss Ratings downgraded shares of NeuroPace from a “sell (d-)” rating to a “sell (e+)” rating in a report on Friday, October 2nd.

View Our Latest Stock Report on NPCE

NeuroPace News Roundup

These are some of the NPCE news items that stood out recently:

  • Positive Sentiment: The CEO bought 11,891 shares for about $99,290, the CFO bought 11,891 shares for about $99,171, and a director purchased 12,500 shares for about $103,625. These purchases may signal confidence in NeuroPace’s prospects, though insider buying does not guarantee a stock rebound. CEO SEC filing CFO SEC filing Director SEC filing
  • Neutral Sentiment: Analyst views are mixed: several firms lowered ratings or price targets, while one report cited a substantially higher average target. Price targets are estimates, not guarantees. Analyst coverage and insider buying
  • Negative Sentiment: Recent commentary highlighted weak implant activity, execution challenges and regulatory risks as concerns for NeuroPace’s RNS growth outlook. Wolfe Research downgraded the stock to Hold; other recent rating cuts add pressure to sentiment. Growth and execution risks

NeuroPace Stock Up 0.2%

NPCE stock opened at $8.22 on Thursday. NeuroPace has a twelve month low of $5.46 and a twelve month high of $19.60. The company has a market cap of $283.20 million, a price-to-earnings ratio of -14.68 and a beta of 1.98. The company has a quick ratio of 4.09, a current ratio of 5.26 and a debt-to-equity ratio of 5.15. The business has a 50 day moving average price of $12.81 and a two-hundred day moving average price of $14.64.

Insider Activity

In other news, CFO Patrick F. Williams acquired 11,891 shares of the stock in a transaction on Tuesday, November 17th. The shares were purchased at an average price of $8.34 per share, for a total transaction of $99,170.94. Following the transaction, the chief financial officer directly owned 79,399 shares of the company’s stock, valued at approximately $662,187.66. This represents a 17.61% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, Director R Scott Huennekens bought 12,500 shares of the company’s stock in a transaction dated Wednesday, November 18th. The shares were purchased at an average cost of $8.29 per share, with a total value of $103,625.00. Following the acquisition, the director directly owned 12,500 shares of the company’s stock, valued at approximately $103,625. This represents a ∞ increase in their position. The disclosure for this purchase is available in the SEC filing. Over the last quarter, insiders have bought 36,282 shares of company stock valued at $302,086. 19.20% of the stock is owned by insiders.

Hedge Funds Weigh In On NeuroPace

A number of hedge funds have recently bought and sold shares of the business. Legal & General Group Plc acquired a new stake in shares of NeuroPace in the second quarter valued at approximately $41,000. Algert Global LLC raised its holdings in NeuroPace by 2.9% in the 2nd quarter. Algert Global LLC now owns 184,774 shares of the company’s stock valued at $2,936,000 after acquiring an additional 5,218 shares in the last quarter. Mitsubishi UFJ Asset Management Co. Ltd. bought a new position in shares of NeuroPace in the second quarter worth $157,000. Entropy Technologies LP acquired a new position in NeuroPace in the third quarter valued at about $146,000. Finally, Lazard Asset Management LLC raised its stake in NeuroPace by 9.8% in the first quarter. Lazard Asset Management LLC now owns 124,305 shares of the company’s stock valued at $1,635,000 after purchasing an additional 11,078 shares in the last quarter. 78.83% of the stock is owned by institutional investors.

NeuroPace Company Profile

(Get Free Report)

NeuroPace, Inc. is a medical technology company focused on treating people with drug-resistant epilepsy. Its primary product is the RNS System, an implanted responsive neurostimulation device designed to detect patterns of abnormal electrical activity in the brain and deliver stimulation in response. The RNS System includes a neurostimulator implanted in the skull and leads placed in or near seizure-onset areas of the brain. Clinicians use the system to review brain activity and adjust treatment, while patients can use accompanying tools to record information about their seizures and share it with their care team.

See Also

Analyst Recommendations for NeuroPace (NASDAQ:NPCE)

Receive News & Ratings for NeuroPace Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NeuroPace and related companies with MarketBeat.com's FREE daily email newsletter.